HT JOINS EU CONSORTIUM LIFETIME
Human Technopole is now an Associate Partner of LifeTime, the pan-European research initiative that aims to revolutionise healthcare by tracking and understanding human diseases at single cell resolution to transform patients’ care and the sustainability of healthcare systems.
Joining the LifeTime community is an important opportunity for Human Technopole to build a strategic network of relevant European partners that share our ambition and goals.
Human Technopole’s mission is fully aligned with LifeTime’s overarching aim to tackle complex human diseases. Specifically, the three defining pillars of LifeTime (single-cell multiomics, organoids and machine learning-based deconvolution) are represented in HT by the close integration of Centres and Core Facilities featuring leading expertise in these fields.
Together with the University of Milan, the European Institute of Oncology (IEO) and the Sacco Hospital, Human Technopole is already part of the Italian branch of the initiative Lifetime for COVID19, which for the upcoming two years will be led by the Head of our Research Centre for Neurogenomics, Prof. Giuseppe Testa.
The LifeTime consortium gathers over 120 leading scientists from over 90 European research institutes. The University of Milan is the Italian partner of the consortium and other Italian associate partners include the European Institute of Oncology, Fondazione Istituto FIRC di Oncologia Molecolare, the Institute for Biomedical Technologies and the Institute of Photonics and Nanotechnologies of the Italian National Research Council as well as many prominent Italian universities.
Share:
You could also like:
-
Italy at the centre of the Genome of Europe project
The Human Technopole, ELIXIR Italia, the national node of the European life sciences research infrastructure coordinated by the National Research Council (CNR), and the Centro Cardiologico Monzino, as the Italian coordinating centre, have been selected as the Italian partners of Genome of Europe (GoE), the largest EU-funded genomic project, whose ultimate goal is to make […]
-
Human Technopole wins 2024 Oscar di Bilancio
On Friday 13 December, at Palazzo Mezzanotte in Milan, the Human Technopole Foundation’s ‘Integrated Report 2023’ received the Oscar di Bilancio in the social enterprises and non-profit organisations category. The award was presented to President Gianmario Verona, Elena Trovesi, Head of Administration, as well as the project leaders Giovanni Selmi, Head of Finance, and Alessandro […]
-
Mosaic Organoids to Study the Brains of Multiple Patients Simultaneously
An international team of scientists from Human Technopole and the University of Milan has developed and validated an innovative approach to studying human brain development across multiple individuals simultaneously using single organoids—laboratory models that replicate key cellular processes of human neurodevelopment. The research paves the way for in vitro population studies. Additionally, the scientists have developed a novel computational method to more accurately quantify the genetic identity of individual cells profiled from multiple individuals concurrently. The findings have been published in Nature Methods.
-
Cancer stem cell morphology predicts glioblastoma growth and resistance
Human Technopole researchers have identified adducin-γ (ADD3) as a crucial regulator of glioblastoma cancer stem cell morphology and intercellular bridges between tumour cells. These connections facilitate communication and allow tumour cells to share resources, evade chemotherapy, and survive in challenging conditions. The study has been funded by AIRC and the findings are published in Life Science Alliance.
-
Colorectal Cancer: ML Enhances Cetuximab Response Predictions
An international collaborative study led by Human Technopole, Candiolo Cancer Institute IRCCS in Turin, the University of Turin, and the Wellcome Sanger Institute in Cambridge (UK) has identified new factors associated with therapeutic response in colorectal cancer. The research has led to the development of a machine-learning model capable of accurately predicting the effects of cetuximab, a drug in clinical use, on different colorectal tumour subtypes. Funded by the AIRC Foundation, the study paves the way to identifying molecular features that could serve as biomarkers for predicting treatment response in patients with this type of cancer.